Evaluation of galectin-1 and galectin-3 levels in patients with bipolar disorder: is galectin-3 associated with treatment response?

Basit Öğe Kaydı
dc.authoridAyaz Nayci, Nagihan/0000-0002-0865-2818
dc.contributor.authorAytekin, Meryem Yuksel
dc.contributor.authorKahve, Aybeniz Civan
dc.contributor.authorEkinci, Rabia Nazik
dc.contributor.authorNural, Arzu Sakalli
dc.contributor.authorCakmak, Isik Batuhan
dc.contributor.authorNayci, Nagihan Ayaz
dc.contributor.authorGoka, Erol
dc.date.accessioned2025-01-21T16:40:38Z
dc.date.available2025-01-21T16:40:38Z
dc.date.issued2024
dc.departmentKırıkkale Üniversitesi
dc.description.abstractObjective: Galectins (Gal), which have been linked with inflammatory response in the central nervous system, may play an important role in the pathogenesis of bipolar disorder. In this study, we investigated whether serum Gal-1 and Gal-3 levels are related to bipolar disorder. Methods: Thirty-six patients diagnosed with bipolar disorder were included. C-reactive protein, Gal-1, Gal-3 serum concentrations were evaluated on the first day of hospitalization and the third week of treatment and were compared with 41 healthy controls. Illness severity was evaluated with the Young Results: Upon hospitalization, the C-reactive protein levels of bipolar disorder patients were significantly higher than in the third week of treatment or in healthy controls. Gal-1 levels on the first day of hospitalization and the third week of treatment were higher than those of healthy controls.There was no significant difference between patient Gal-3 levels upon hospitalization and those of healthy controls; at the end of the third week of treatment, Gal-3 levels were significantly higher than on the first day of hospitalization. Conclusion: Our study is the first to show a change in Gal levels after treatment and to evaluate the role of Gal in bipolar disorder. Gal-1 may play a role in the pathophysiology of bipolar disorder. Gal-3 could be a biomarker candidate for assessing treatment response.
dc.description.sponsorshipScientific Research Projects Unit of the Health Sciences University of the Republic of Turkey [2021/150]
dc.description.sponsorshipAcknowledgements The biochemical analyses in this study were supported by the Scientific Research Projects Unit of the Health Sciences University of the Republic of Turkey (Project No. 2021/150) .
dc.identifier.doi10.47626/1516-4446-2024-3535
dc.identifier.issn1516-4446
dc.identifier.issn1809-452X
dc.identifier.pmid38767861
dc.identifier.urihttps://doi.org/10.47626/1516-4446-2024-3535
dc.identifier.urihttps://hdl.handle.net/20.500.12587/24733
dc.identifier.volume46
dc.identifier.wosWOS:001374115300001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherAssoc Brasileira Psiquiatria
dc.relation.ispartofBrazilian Journal of Psychiatry
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241229
dc.subjectGalectins; bipolar disorder; inflammation; mood disorders; biomarkers
dc.titleEvaluation of galectin-1 and galectin-3 levels in patients with bipolar disorder: is galectin-3 associated with treatment response?
dc.typeArticle

Dosyalar

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu